Is Egrifta (Tesamorelin) Legal in South Carolina?

Federal Legal Status of Tesamorelin

Tesamorelin is a legally manufactured, FDA-approved prescription medicine. It is not a research chemical, not a gray-area compound, and not a controlled substance at the federal level.

The FDA first approved Egrifta (tesamorelin for injection, 2 mg) on November 10, 2010, under NDA 022505, for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [1]. A reformulated 2 mg single-vial version (Egrifta SV) received approval in 2019 [2]. Both approvals are held by Theratechnologies Inc. And are listed in the FDA Orange Book as reference-listed drugs [3].

What Tesamorelin Is and Is Not

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It stimulates pituitary release of endogenous growth hormone rather than supplying exogenous GH directly [4]. That distinction matters legally: recombinant human growth hormone (somatropin) is explicitly restricted to enumerated indications under 21 U.S.C. § 333(e), a provision that does not apply to GHRH analogues like tesamorelin [5].

Because tesamorelin is not somatropin and is not a DEA-scheduled substance, it does not trigger the additional prescribing restrictions that apply to HGH. A licensed prescriber may write a tesamorelin prescription for any indication they judge appropriate under their standard of care, though off-label prescribing carries its own professional responsibility considerations.

The FDA Orange Book and What It Means for Patients

Orange Book listing means a generic applicant must demonstrate bioequivalence before marketing a copy. No generic tesamorelin product has received FDA approval as of January 2025 [3]. Patients receiving branded Egrifta or Egrifta SV through a retail pharmacy are receiving a federally approved, quality-assured product.

Off-Label Use: Is It Legal?

Off-label prescribing of FDA-approved drugs is legal under federal law and is a routine part of medical practice [6]. The FDA does not restrict how physicians prescribe approved drugs once those drugs are on the market. A South Carolina physician who prescribes tesamorelin for anti-aging, body composition, or other non-HAL purposes is not violating federal drug law, though they remain subject to state medical practice standards.

South Carolina State Law and Tesamorelin

South Carolina has not enacted any statute specifically restricting tesamorelin. Prescribing and dispensing follow the general framework of the South Carolina Pharmacy Practice Act (S.C. Code Ann. § 40-43-10 et seq.) and the South Carolina Medical Practice Act (S.C. Code Ann. § 40-47-10 et seq.).

Controlled Substance Scheduling in South Carolina

The South Carolina Controlled Substances Act (S.C. Code Ann. § 44-53-110 et seq.) mirrors the federal DEA schedule. Tesamorelin does not appear on the South Carolina Schedule I through V lists [7]. It is not a controlled substance under state law. A prescriber writing tesamorelin does not need a DEA number specifically for that drug, though most physicians hold one.

South Carolina Board of Medical Examiners Standards

The South Carolina Board of Medical Examiners requires that any prescription be issued for a legitimate medical purpose within a valid patient-prescriber relationship [8]. For tesamorelin, that means:

• A documented clinical evaluation (in-person or via a compliant telehealth encounter)
• A medical history that supports the prescribing decision
• Informed consent covering known risks, including fluid retention, arthralgias, and glucose intolerance [9]

Prescribers who issue tesamorelin prescriptions without an adequate evaluation may face board discipline under S.C. Code Ann. § 40-47-110, but the drug itself is not prohibited.

South Carolina Board of Pharmacy

The South Carolina Board of Pharmacy licenses retail pharmacies, mail-order pharmacies, and compounding pharmacies operating in or shipping into the state [10]. A licensed pharmacist may dispense Egrifta or Egrifta SV against a valid prescription. Compounded tesamorelin formulations are subject to the additional federal and state compounding rules described in the next section.

Compounded Tesamorelin: A Narrower Legal Space

Branded Egrifta is straightforwardly legal. Compounded tesamorelin requires more careful analysis because federal compounding law imposes independent restrictions beyond simple prescription requirements.

How 503A and 503B Compounding Pharmacies Differ

Under the Drug Quality and Security Act of 2013, there are two categories of compounding pharmacy [11]:

503A pharmacies compound for individual patients based on a specific prescription. They are licensed at the state level (in SC, by the Board of Pharmacy) and are exempt from FDA new-drug approval requirements if they meet certain conditions, including not copying commercially available drugs and not using bulk drug substances that appear on the FDA's "Category 1 Nominated Substances" list.

503B outsourcing facilities produce larger batches without patient-specific prescriptions and are registered with the FDA. They face Current Good Manufacturing Practice (cGMP) requirements and can ship to practitioners for office use [12].

Where Tesamorelin Sits on the FDA Bulk Drug Lists

The FDA maintains two lists of bulk substances relevant to compounding:

1. The 503A Bulks List (substances that may be used in 503A compounding): Tesamorelin has been nominated but, as of January 2025, the FDA has not placed it on the positive 503A bulks list [13]. This means a 503A pharmacy that compounds tesamorelin from raw bulk powder is operating in a legally uncertain area.

2. The 503B Bulks List: Similarly, tesamorelin is not on the FDA's published 503B bulks list [14].

The FDA's position on compounding a drug that is already commercially available in an FDA-approved form is cautious. FDA guidance states that compounding copies of commercially available drugs is generally impermissible for 503A pharmacies absent a showing of clinical difference (e.g., a specific formulation need) [15].

Practical implication for South Carolina patients: If you receive a prescription for compounded tesamorelin from a 503A pharmacy in South Carolina, confirm that the pharmacy can document a clinical rationale for why the compounded version is necessary rather than branded Egrifta. Pharmacies that compound tesamorelin without such documentation may be in violation of FDA policy, even if South Carolina law itself does not specifically prohibit it.

Vials vs. Subcutaneous Pellets and Other Novel Forms

Some compounding pharmacies offer tesamorelin in non-standard forms (nasal sprays, oral troches, blended peptide combinations). The FDA has not evaluated these formulations for safety or efficacy. Patients considering such formulations should understand that the clinical trial data supporting tesamorelin's effects, including the randomized controlled trials described below, were conducted with subcutaneous injection [16].

Clinical Evidence Supporting Tesamorelin's Approved Use

Understanding the clinical trial record helps patients and prescribers make informed decisions about tesamorelin's legitimate medical applications.

The Phase 3 Registration Trials for HAL

Two key Phase 3 trials (LIPO-010 and LIPO-011, combined N=816) evaluated tesamorelin 2 mg subcutaneous daily versus placebo in HIV-infected adults with abdominal lipodystrophy [17]. At 26 weeks, tesamorelin produced a mean 15.2% reduction in visceral adipose tissue (VAT) by CT scan compared with a 4.9% reduction in placebo (P<0.001) [17]. The FDA relied on these data in granting approval.

A 52-week open-label extension showed that VAT reduction was maintained with continued therapy and reversed within 6 months after discontinuation [18]. Triglycerides fell by a mean of 50.5 mg/dL in the tesamorelin arm at 26 weeks [17].

Metabolic Safety Data

Glucose intolerance is the most clinically significant adverse effect. In the combined Phase 3 dataset, the incidence of diabetes mellitus was 3.6% with tesamorelin versus 1.4% with placebo [9]. The prescribing information (FDA label) therefore recommends glucose monitoring and caution in patients with pre-existing impaired fasting glucose [9]. The American Association of Clinical Endocrinology (AACE) notes that growth hormone axis stimulants generally carry a class risk of insulin resistance [19].

Evidence Outside the Approved Indication

Small studies have examined tesamorelin in non-HIV populations. A 20-week randomized trial (N=61) in adults with abdominal obesity but without HIV showed statistically significant VAT reduction with tesamorelin versus placebo [20]. IGF-1 levels rose by a mean of 181 ng/mL in the tesamorelin group [20]. These data do not establish FDA-approved indications but are relevant to off-label clinical decision-making.

How to Get Egrifta (Tesamorelin) in South Carolina

The legal path to obtaining tesamorelin in South Carolina involves three steps: a clinical evaluation, a valid prescription, and a licensed dispensing pharmacy.

Step 1: Find a Qualified Prescriber

Any South Carolina-licensed physician (MD or DO), advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant (PA) operating under a supervising physician may prescribe tesamorelin [8]. Endocrinologists, infectious disease specialists, and anti-aging or functional medicine practitioners are the most common prescribers.

Telehealth prescribing is legal in South Carolina under S.C. Code Ann. § 40-47-37, provided the prescriber establishes a valid patient-prescriber relationship before issuing the prescription [8]. HealthRX connects South Carolina residents with board-certified physicians who can evaluate tesamorelin candidacy through a secure telehealth visit.

Step 2: The Clinical Evaluation

A thorough evaluation for tesamorelin should include:

• Baseline IGF-1 level to assess GH axis status and to establish a monitoring reference point
• Fasting glucose and HbA1c given the glucose intolerance risk
• Fasting lipid panel (tesamorelin lowers triglycerides in HAL patients; baseline data are useful)
• Review of contraindications: active malignancy, pregnancy, hypersensitivity to tesamorelin or mannitol [9]
• Disclosure of the approved vs. Off-label nature of the intended use, if applicable

The FDA-approved prescribing information (full label) for Egrifta SV provides the reference standard for these pre-treatment assessments [9].

Step 3: Pharmacy Dispensing Options

Once a prescription is issued, patients in South Carolina have several dispensing options:

Retail and mail-order pharmacies: Egrifta and Egrifta SV are available through specialty pharmacies with a valid prescription. Because branded Egrifta can be expensive without insurance coverage, patients with HIV-associated lipodystrophy may qualify for the Theratechnologies patient assistance program.

503B outsourcing facilities: A handful of FDA-registered 503B facilities produce tesamorelin for practitioner office use. Receiving tesamorelin from a 503B facility is legal provided the facility is FDA-registered and the prescribing physician is licensed in South Carolina [12].

503A compounding pharmacies: Legal only under the conditions described above. Verify the pharmacy's South Carolina Board of Pharmacy license [10] before using a 503A compounder for tesamorelin.

Monitoring During Tesamorelin Therapy

South Carolina prescribers following the Egrifta label and AACE guidance should monitor patients on tesamorelin at regular intervals [9, 19].

Laboratory Monitoring Schedule

| Parameter | Baseline | 3 Months | 6 Months | Annually | |---|---|---|---|---| | IGF-1 | Yes | Yes | Yes | Yes | | Fasting glucose / HbA1c | Yes | Yes | Yes | Yes | | Fasting triglycerides | Yes | No | Yes | Yes | | Liver function tests | Yes | No | As indicated | As indicated |

IGF-1 should be kept within age-adjusted normal ranges. The prescribing information advises discontinuing tesamorelin if IGF-1 rises above 3 standard deviations above mean for age [9].

Clinical Response Assessment

VAT reduction is the registered endpoint but is measured by CT in clinical trials, which is not routinely available outside research settings. In clinical practice, waist circumference and patient-reported body image are practical proxies. The registration trials used CT-measured VAT; waist circumference correlated moderately with VAT change (r=0.54) in the LIPO-010 dataset [17].

Insurance Coverage and Cost in South Carolina

Branded Egrifta is covered by most major commercial insurance plans for the FDA-approved indication (HIV-associated lipodystrophy) with prior authorization. South Carolina Medicaid (Healthy Connections) covers Egrifta for HAL when medical necessity criteria are met [21]. Off-label use is generally not covered by insurance.

Without coverage, the average wholesale price (AWP) for Egrifta SV 2 mg/vial runs approximately $1,400 to $1,600 per 30-day supply based on published drug pricing databases. Compounded tesamorelin from a 503A pharmacy typically costs $150 to $400 per month, which explains its popularity despite the legal ambiguity.

Summary of Legal Risk by Tesamorelin Route in South Carolina

Different pathways carry different levels of legal clarity, which prescribers and patients should understand before choosing a route.

| Route | Federal Status | SC State Status | Recommended? | |---|---|---|---| | Branded Egrifta via retail pharmacy | Fully legal | Fully legal | Yes | | Branded Egrifta via mail-order | Fully legal | Fully legal | Yes | | 503B outsourcing facility (tesamorelin) | Legal if FDA-registered | Legal | Yes, with verification | | 503A compounding (bulk tesamorelin) | Legally uncertain (not on 503A bulks list) | Not specifically prohibited | Only with documented clinical rationale | | Research use without IRB approval | Not legal for human use | Not legal | No |